Tinubu Square Appoints Aurelien Pelletier as Chief Product & Technology Officer
26.1.2022 16:00:00 EET | Business Wire | Press release
Tinubu Square, a proven SaaS solutions editor and a leader in enabling Credit Insurance & Surety digital transformation, is expanding. To sustain its current growth, Tinubu recently made acquisitions, onboarded new technologies and is equipping itself with the capabilities to achieve its ambitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005498/en/
Tinubu Square - Aurelien PELLETIER - CPTO
This is reflected in the investments made in its products, but also in the evolution of its organization, such as the arrival of Aurélien Pelletier as Chief Product & Technology Officer, a recognized specialist in cutting-edge digital technology.
His role will be to accelerate Tinubu’s progression as a high-performance "software factory" and drive its products' evolution toward an end-to-end technological platform, a "Digital Highway" for our Credit Insurance & Surety customers connecting their entire ecosystem.
Tinubu’s endeavor and our new CPTO’s mission are about fostering flexibility and agility for a faster and still highly reliable technical delivery. In short, uphold our promise, "You are an insurer, and you want to focus on your field of expertise. We can bring to you the best technology to enable you do your business more efficiently."
Aurélien has more than 20 years of experience working in the tech industry providing best-in-class services, and a proven 10-year track record at C-level positions.
At the beginning of the millennium, he worked in the software design and delivery consulting services field for Atos as a technical architect working on innovation. In 2012, he joined Sfeir as CTO to advance its position into a leader on digital transformation and cloud computing projects. Then, from 2017 to 2020, he became the CTO of PrestaShop, a leading open-source e-commerce solution, where he defined and led the tech vision and strategy of the company.
With his deep experience in Agile methodologies, DevOps, continuous delivery, open sources, cloud computing and Web APIs, Aurélien is not only the perfect match for Tinubu’s objectives, but the love for his fields of expertise is also what drives him.
After having worked on all types of information system architectures, today he has developed a passion for organizational architecture – and the many bridges that exist between these two specialties.
“We are continuously working at strengthening the technological side of Tinubu’s solutions and having on board someone like Aurélien who masters the most advanced technologies and methodologies is what we were looking for. He is a great asset and resource to keep improving our ability to bring best-in-class technology to our customers through our SaaS platform,” declares Olivier Placca, Deputy CEO of Tinubu Square.
“I have known Tinubu for a long time and have a lot of trust in the executive team and its vision. I am excited by the ambitions, the potential and the international scope that define Tinubu. I think that combination is a very strong point of attraction for new talents and for those who already have experience working on a global market,” states Aurélien Pelletier.
About Tinubu Square – www.tinubu.com — @TinubuGroup
Tinubu Square is the industry-leading SaaS platform vendor, enabling Credit Insurance & Surety digital transformation. For more than 20 years, Tinubu Square has provided Credit & Surety insurers across the globe with software and services allowing them to offer best-in-class customer experience, as well as significantly reduce their exposure to risk and their financial, operational, and technical costs. Tinubu Square has an international footprint with customers in over 20 countries, including 30 of the top 60 worldwide Credit & Surety underwriters.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005498/en/
Contact information
Press contact
Tinubu Square: Lotta Bonde
lbe@tinubu.com
Phone: +33 1 55 95 85 85
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom